Epiregulin consists of 46 amino acid residues. Its secondary structure contains approximately 30 percent of β-sheet in the strand. Some of the residues form loops and turns due to the hydrogen bonding. The percentage of β-sheet in epiregulin depends on the domain and the secondary structures that they occupy. The polymeric molecules of epiregulin has the formula weight of 5280.1 g/mol with a polypeptide(L), a polymer type.
Structural motifs in most proteins have typical connections in an all β motif. Meaning that the polypeptide chains do not make a crossover connection or in so far as this type of connection has not been observed. Epiregulin is one of the proteins that occupies a typical connection in all β motif. Furthermore, as the structure of epiregulin forms a chain in an all β motif, it also forms β hairpin structural motif. A β hairpin is when the two adjacent anti-parallel β strands connected by a β-turn.
Epiregulin is a member of the epidermal growth factor family. Epiregulin can function as a ligand of epidermal growth factor receptor (EGFR), as well as a ligand of most members of the ERBB (v-erb-b2 oncogene homolog) family of tyrosine-kinase receptors. The secondary structure at the C-terminus epiregulin is different from other epidermal growth factor family ligands because of the lack of hydrogen bonds. The structural difference at the C-terminus may provide an explanation for the reduced binding affinity of epiregulin to the ERBB receptors.
^ abcdePDB1K36; Sato K, Nakamura T, Mizuguchi M, Miura K, Tada M, Aizawa T, Gomi T, Miyamoto K, Kawano K (October 2003). "Solution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinity". FEBS Lett.553 (3): 232–8. doi:10.1016/S0014-5793(03)01005-6. PMID14572630.
Yamamoto T, Akisue T, Marui T et al. (2004). "Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma.". Anticancer Res.24 (3b): 2007–10. PMID15274392.CS1 maint: Explicit use of et al. (link)
Cho MC, Choi HS, Lee S et al. (2008). "Epiregulin expression by Ets-1 and ERK signaling pathway in Ki-ras-transformed cells.". Biochem. Biophys. Res. Commun.377 (3): 832–7. doi:10.1016/j.bbrc.2008.10.053. PMID18948081.CS1 maint: Explicit use of et al. (link)
Lindvall C, Hou M, Komurasaki T et al. (2003). "Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene.". Cancer Res.63 (8): 1743–7. PMID12702554.CS1 maint: Explicit use of et al. (link)
Morita S, Shirakata Y, Shiraishi A et al. (2007). "Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members.". Mol. Vis.13: 2119–28. PMID18079685.CS1 maint: Explicit use of et al. (link)
Freimann S, Ben-Ami I, Dantes A et al. (2004). "EGF-like factor epiregulin and amphiregulin expression is regulated by gonadotropins/cAMP in human ovarian follicular cells.". Biochem. Biophys. Res. Commun.324 (2): 829–34. doi:10.1016/j.bbrc.2004.09.129. PMID15474502.CS1 maint: Explicit use of et al. (link)
Ben-Ami I, Armon L, Freimann S et al. (2009). "EGF-like growth factors as LH mediators in the human corpus luteum.". Hum. Reprod.24 (1): 176–84. doi:10.1093/humrep/den359. PMID18835871.CS1 maint: Explicit use of et al. (link)
Shigeishi H, Higashikawa K, Hiraoka M et al. (2008). "Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas.". Oncol. Rep.19 (6): 1557–64. doi:10.3892/or.19.6.1557. PMID18497965.CS1 maint: Explicit use of et al. (link)
Draper BK, Komurasaki T, Davidson MK, Nanney LB (2003). "Epiregulin is more potent than EGF or TGFalpha in promoting in vitro wound closure due to enhanced ERK/MAPK activation.". J. Cell. Biochem.89 (6): 1126–37. doi:10.1002/jcb.10584. PMID12898511.
Révillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP (January 2008). "ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis". Ann. Oncol.19 (1): 73–80. doi:10.1093/annonc/mdm431. PMID17962208.
Ben-Ami I, Freimann S, Armon L et al. (2006). "PGE2 up-regulates EGF-like growth factor biosynthesis in human granulosa cells: new insights into the coordination between PGE2 and LH in ovulation.". Mol. Hum. Reprod.12 (10): 593–9. doi:10.1093/molehr/gal068. PMID16888076.CS1 maint: Explicit use of et al. (link)
Takahashi M, Hayashi K, Yoshida K et al. (2003). "Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells.". Circulation108 (20): 2524–9. doi:10.1161/01.CIR.0000096482.02567.8C. PMID14581411.CS1 maint: Explicit use of et al. (link)
Lasky-Su J, Neale BM, Franke B et al. (2008). "Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations.". Am. J. Med. Genet. B Neuropsychiatr. Genet.147B (8): 1345–54. doi:10.1002/ajmg.b.30867. PMID18821565.CS1 maint: Explicit use of et al. (link)
Gupta GP, Nguyen DX, Chiang AC et al. (2007). "Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.". Nature446 (7137): 765–70. doi:10.1038/nature05760. PMID17429393.CS1 maint: Explicit use of et al. (link)
Shirakata Y, Komurasaki T, Toyoda H et al. (2000). "Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes.". J. Biol. Chem.275 (8): 5748–53. doi:10.1074/jbc.275.8.5748. PMID10681561.CS1 maint: Explicit use of et al. (link)